Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days,...
ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions such as major depressive disorder, addiction and end‐of‐life anxiety. Previous studies in both animals and humans have confirmed the effects of these drugs on neuronal activity and plasticity. However, the understanding of the mechanisms of action of...
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ability to restore our mental health. Psilocybin (active ingredient in hallucinogenic mushrooms), LSD (derived from compounds from ergot), dimethyltryptamine (or DMT, part of the composition of ayahuasca), mescaline (derived from peyote), but also...
February 26, 2025Stanisław Adamczyk, Małgorzata Paczyńska, Anastasia Ruban et al.1 citation
preprint
Psychedelic substances have the potential to induce profound alterations in cognition, emotionality, and sensory perception. The quality and intensity of these subjective effects exhibit high intra- and inter-individual variability, which can potentially be accounted for by the variability in contexts in which psychedelics are used. Therefore, the aim of the present cross-sectional study was to...
Medical ScienceFebruary 25, 2025Jakub Pudźwa, Kamil Gibczyński, Karol Leśniewski et al.
Objective: The purpose of the following review was to summarize the recent studies on proposed mechanisms of action of psychedelic drugs (psilocybin, MDMA, LSD), their therapeutic potential in mental disorders (depression, PTSD, addictions), and the evaluation of their safety. This review also discusses the barriers to the clinical implementation of these agents. Methodology: The paper combines...
Clinical ToxicologyFebruary 20, 2025Courtney Temple, Matthew S. Correia, Ma Gonzaga et al.3 citations
The labeling of psychoactive mushroom gummies we tested was overall inaccurate. Products suggesting Amanita muscaria content instead contained serotonergic tryptamines, including some which falsely claimed to be free of psilocybin.
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psychedelic-assisted therapy (PAT), in which serotonergic agents like psilocybin are administered in a psychotherapeutic context, has shown promise for refractory psychiatric disorders, including major depressive disorder and post-traumatic stress...
PolymatheiaFebruary 16, 2025Ernesto Grillo Rabello, Giuliana de Paula Oliveira, Lucas Conforti Protti et al.1 citation
The encounter of clinical psychology with psychedelic compounds, plants, and mushrooms opens up new possibilities for psychotherapy practices. In the Schizoanalysis of Gilles Deleuze and Félix Guattari, conceptual and experimental tools are found that not only assist in thinking about the psychedelic experience but also enrich clinical practice. The concept of the Body without Organs, which...
Psychoactive substances used for recreational purposes have mind-altering effects, but systematic evaluation of these effects is largely limited to self-reports. Automated analysis of expressed language (speech and written text) using natural language processing (NLP) tools can provide objective readouts of mental states. In this pre-registered systematic review, we investigate findings from...
Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors...